Information updates

Temporary shortage of Stallergenes Greer allergen immunotherapy products

22 March 2018

Stallergenes Greer has notified ASCIA of a temporary shortage in the supply of the subcutaneous (SCIT) injectable allergen immunotherapy products. The supply of Stallergenes Greer sublingual allergen immunotherapy (SLIT) products is not impacted.  Despite this temporary supply shortage from their Antony manufacturing site in France, Stallergenes Greer has existing local stock in Australia and New Zealand. This should enable the continued supply of the full range of their SCIT and SLIT products, with the exception of ALUSTAL 5 grass mix (initial 3 vials).  

Patients who are currently receiving (or are being considered) for treatment with Stallergenes Greer SCIT products should speak with their doctor about the potential impact of this temporary supply shortage on their management.

Stallergenes Greer is continuing to upgrade its manufacturing facility and processes at their Antony site in France. Significant improvements supported by substantial investments have already been implemented proactively over the past few months to deliver products that meet the highest quality standards. However, the improvements they are now undertaking will be on a larger scale and will take more time than originally anticipated, resulting in longer manufacturing lead times and temporary shortages.

Stallergenes Greer regrets the impact of this transition phase at their manufacturing site, which is focused on ensuring the continued availability of quality allergen immunotherapy products. All Stallergenes Greer teams are working to make these products available again. Further updates will be provided as soon as more information is available.

Mod ASCIA Member
Donate to AIFA
go to NAS website

ASCIA is the peak professional body of clinical immunology and allergy in Australia and New Zealand
ASCIA promotes and advances the study and knowledge of allergy and other immune diseases

Quick Links


ASCIA is a registered trademark of the Australasian Society of Clinical Immunology and Allergy. All content is subject to copyright for the Australasian Society of Clinical Immunology and Allergy. Read more...

The content for the website is developed and approved by ASCIA Committee and ASCIA Working Party Members. Read more...

Disclaimer I Privacy

The ASCIA website is intended for use by ASCIA members, health professionals and the general public. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

Sponsors | Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites. 

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.



This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.